Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged Somatorelin (TH9507) Treatment in Adolescents with Isolated Hypothalamic Growth Hormone Deficiency
2004-002125-42Phase 3Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of growth hormone releasing hormone 1-44 in growth hormone deficiency (GHD), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Change in IGF-I levels. Started Aug 2007; status: active.
02
Drugs
growth hormone releasing hormone 1-44
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2004-002125-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002125-42.